vrs you're basing your argument on trying to pick little...

  1. 1,034 Posts.
    lightbulb Created with Sketch. 431
    vrs you're basing your argument on trying to pick little holes at differences in the patient cohort without acknowledging the whole picture.

    I can do the same by pointing to the slide attached which could argue the other way, ie the Lupin cohort had a greater % of 20 lesions or more and were more heavily pre-treated than the warmth group - on these data points you could argue that the Lupin cohort was more advanced and your argument doesn't hold as firmly.

    In addition the Lupin results showed a greater % of patients to achieve a PSA reduction (86% vs 73%) and greater % to achieve more than 50% PSA reduction

    The comparison is never going to be like for like and was intended to provide a degree of context.

    Importantly imo you have not been able to conclude that Veyonda does not provide additional efficacy vs lutetium alone and that's the key part of this.

    The Lupin studies are not yet finished either so I look forward to the market's (and your) reaction when 71% is adjusted to +100%!
    https://hotcopper.com.au/data/attachments/3228/3228581-45e008bc967f479886dff5d11bdf1f5f.jpg
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
5.1¢
Change
0.001(2.00%)
Mkt cap ! $14.90M
Open High Low Value Volume
5.1¢ 5.1¢ 5.1¢ $3.294K 64.59K

Buyers (Bids)

No. Vol. Price($)
1 763 5.0¢
 

Sellers (Offers)

Price($) Vol. No.
5.1¢ 125299 2
View Market Depth
Last trade - 11.37am 07/07/2025 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.